Skip to main content

Advertisement

SpringerLink
Log in

Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents

  • Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Nephrogenic systemic fibrosis (NSF) is a disease seen exclusively in patients with decreased renal function. The use of gadolinium-based contrast agents (GBCAs) has a strong association with NSF. Linear non-ionic GBCAs that are more prone to release free gadolinium are the more likely to cause NSF. The number of reported cases has increased recently, and there are currently nine pediatric cases, the patients ranging in age from 8 years to 19 years, and the oldest adult patient is 87 years of age. The most successful treatment is improvement of renal function with renal transplantation or with recovery of acute kidney injury. NSF can be severely debilitating and even fatal. Avoidance of a GBCA in patients at risk, or limitation of the dose in the patients who need gadolinium enhancement, is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000–1001

    CAS  PubMed  Google Scholar 

  2. Daram SR, Cortese CM, Bastani B (2005) Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 46:754–759

    PubMed  Google Scholar 

  3. Auron A, Shao L, Warady BA (2006) Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 21:1307–1311

    PubMed  Google Scholar 

  4. Jain SM, Wesson S, Hassanein A, Canova E, Hoy M, Fennell RS, Dharnidharka VR (2004) Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 19:467–470

    PubMed  Google Scholar 

  5. Jan F, Segal JM, Dyer J, LeBoit P, Siegfried E, Frieden IJ (2003) Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 143:678–681

    PubMed  Google Scholar 

  6. Cowper SE (2003) Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15:785–790

    PubMed  Google Scholar 

  7. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35:238–249

    PubMed  PubMed Central  Google Scholar 

  8. Streams BN, Liu V, Liegeois N, Moschella SM (2003) Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol 48:42–47

    PubMed  Google Scholar 

  9. Cowper SE, Bucala R (2003) Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 25:358

    PubMed  Google Scholar 

  10. Jimenez SA, Artlett CM, Sandorfi N, Derk C, Latinis K, Sawaya H, Haddad R, Shanahan JC (2004) Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50:2660–2666

    CAS  PubMed  Google Scholar 

  11. Parsons AC, Yosipovitch G, Sheehan DJ, Sangüeza OP, Greenberg CS, Sane DC (2007) Transglutaminases: the missing link in nephrogenic systemic fibrosis. Am J Dermatopathol 29:433–436

    PubMed  Google Scholar 

  12. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23:383–393

    CAS  PubMed  Google Scholar 

  13. Levine JM, Taylor RA, Elman LB, Bird SJ, Lavi E, Stolzenberg ED, McGarvey ML, Asbury AK, Jimenez SA (2004) Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 30:569–577

    PubMed  Google Scholar 

  14. Keyrouz S, Rudnicki SA (2007) Neuromuscular involvement in nephrogenic systemic fibrosis. J Clin Neuromuscul Dis 9:297–302

    PubMed  Google Scholar 

  15. Krous H, Breisch E, Chadwick A, Pinckney L, Malicki DM, Benador N (2007) Nephrogenic systemic fibrosis with multiorgan involvement in a teenage male after lymphoma, Ewing sarcoma, end stage renal disease, and hemodialysis. Pediatr Dev Pathol 10:395–402

    PubMed  Google Scholar 

  16. Kucher C, Steere J, Elenitsas R, Siegel DL, Xu X (2006) Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 54:S31–34

    PubMed  Google Scholar 

  17. Centers for Disease Control and Prevention (CDC) (2007) Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents—St Louis, Missouri, 2002–2006. MMWR Morb Mortal Wkly Rep 56:137–141

    Google Scholar 

  18. Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH (2007) Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245:168–175

    PubMed  Google Scholar 

  19. Richmond H, Zwerner J, Kim Y, Fiorentino D (2007) Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol 143:1025–1030

    PubMed  Google Scholar 

  20. Todd DJ, Kagan A, Chibnik LB, Kay J (2007) Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 56:3433–3441

    PubMed  Google Scholar 

  21. Wahba IM, Simpson EL, White K (2007) Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 7:2425–2432

    CAS  PubMed  Google Scholar 

  22. Weiss AS, Lucia MS, Teitelbaum I (2007) A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nat Clin Pract Nephrol 3:111–115

    PubMed  Google Scholar 

  23. Kucher C, Xu X, Pasha T, Elenitsas R (2005) Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol 32:484–490

    PubMed  Google Scholar 

  24. Gelpi E, de la Paz MP, Terracini B, Abaitua I, de la Cámara AG, Kilbourne EM, Lahoz C, Nemery B, Philen RM, Soldevilla L, Tarkowski S, WHO/CISAT Scientific Committee for the Toxic Oil Syndrome. Centro de Investigación para el Síndrome del Aceite Tóxico (2002) The Spanish toxic oil syndrome 20 years after its onset: a multidisciplinary review of scientific knowledge. Environ Health Perspect 110:457–464

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Silver RM, Heyes MP, Maize JC, Quearry B, Vionnet-Fuasset M, Sternberg EM (1990) Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med 322:874–881

    CAS  PubMed  Google Scholar 

  26. Grobner T (2006) Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108

    CAS  PubMed  Google Scholar 

  27. Danish Medicines Agency (online 29 May 2006) Investigation of the safety of MRI contrast medium Omniscan [press release] [https://doi.org/www.dkma.dk/1024/visUKLSArtikel.asp?artikelID=8931]

  28. Penfield JG, Reilly RF Jr (2007) What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol 3:654–668

    PubMed  Google Scholar 

  29. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 188:586–592

    PubMed  Google Scholar 

  30. Deo A, Fogel M, Cowper SE (2007) Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2:264–267

    PubMed  Google Scholar 

  31. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN (2007) Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 22:3179–3185

    CAS  PubMed  Google Scholar 

  32. Reilly RF (2008) Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 3:747–751

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Gibby WA, Gibby KA, Gibby WA (2004) Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 39:138–142

    PubMed  Google Scholar 

  34. High WA, Ayers RA, Chandler J, Zito G, Cowper SE (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:21–26

    PubMed  Google Scholar 

  35. Thakral C, Abraham JL (2007) Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of gadolinium deposits in skin. J Electron Microsc 56:181–187

    Google Scholar 

  36. Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P (2007) Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158:273–280

    PubMed  Google Scholar 

  37. High WA, Ayers RA, Cowper SE (2007) Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:710–712

    PubMed  Google Scholar 

  38. Saussereau E, Lacroix C, Cattaneo A, Mahieu L, Goulle JP (2008) Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis. Forensic Sci 176:54–57

    CAS  Google Scholar 

  39. Morcos SK (2007) Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 80:73–76

    CAS  PubMed  Google Scholar 

  40. Thomsen HS, Marckmann P, Logager VB (2007) Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 7:130–137

    PubMed  PubMed Central  Google Scholar 

  41. Wedeking P, Kumar K, Tweedle MF (1992) Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging 10:641–648

    CAS  PubMed  Google Scholar 

  42. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20:563–576

    CAS  PubMed  Google Scholar 

  43. Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5:491–502

    CAS  PubMed  Google Scholar 

  44. European Medicines Agency: EPARs for Authorised Medicinal Products for Human Use. Available at https://doi.org/www.emea.europa.eu/humandocs/Humans/EPAR/optimark/optimark.htm, accessed 29 November 2007

  45. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148–157

    PubMed  Google Scholar 

  46. Saab G, Abu-Alfa A (2007) Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis? Radiology 244:930–931; author reply 931–932

    PubMed  Google Scholar 

  47. US Food and Drug Administration: Information on Gadolinium-Containing Contrast Agents. Available at https://doi.org/www.fda.gov/cder/drug/infopage/gcca/default.htm

  48. Grobner T, Prischl FC (2007) Gadolinium and nephrogenic systemic fibrosis. Kidney Int 72:260–264

    CAS  PubMed  Google Scholar 

  49. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362

    PubMed  Google Scholar 

  50. Hubbard V, Davenport A, Jarmulowicz M, Rustin M (2003) Scleromyxoedema-like changes in four renal dialysis patients. Br J Dermatol 148:563–568

    CAS  PubMed  Google Scholar 

  51. Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME (2003) Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 48:55–60

    PubMed  Google Scholar 

  52. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD (2003) Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114:563–572

    PubMed  Google Scholar 

  53. Goveia M, Chan BP, Patel PR (2007) Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. J Am Acad Dermatol 57:725–727

    PubMed  Google Scholar 

  54. Perazella MA, Ishibe S, Perazella MA, Reilly RF (2003) Nephrogenic fibrosing dermopathy: an unusual skin condition associated with kidney disease. Semin Dial 16:276–280

    PubMed  Google Scholar 

  55. Pieringer H, Schmekal B, Janko O, Biesenbach G (2007) Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. Nephrol Dial Transplant 22:3094

    PubMed  Google Scholar 

  56. Gilliet M, Cozzio A, Burg G, Nestle FO (2005) Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 152:531–536

    CAS  PubMed  Google Scholar 

  57. Kintossou R, D’Incan M, Chauveau D, Bens G, Franck F, Dauplat MM, Viraben R, Déchelotte P, Souteyrand P (2007) Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis: role of gadolinium? Ann Dermatol Venereol 134:667–671

    CAS  PubMed  Google Scholar 

  58. Lauchli S, Zortea-Caflisch C, Nestle FO, Burg G, Kempf W (2004) Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 208:278–280

    PubMed  Google Scholar 

  59. Steen H, Schwenger V (2007) Good MRI images: to Gad or not to Gad? Pediatr Nephrol 22:1239–1242

    PubMed  PubMed Central  Google Scholar 

  60. Thomsen HS, Almen T, Morcos SK (2002) Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 12:2600–2605

    PubMed  Google Scholar 

  61. Morcos SK, Thomsen HS, Webb JA (1999) Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 9:1602–1613

    CAS  PubMed  Google Scholar 

  62. Blondin D, Koester A, Andersen K, Kurz KD, Moedder U, Cohnen M (2007) Renal transplant failure due to urologic complications: comparison of static fluid with contrast-enhanced magnetic resonance urography. Eur J Radiol DOI https://doi.org/10.1016/j.ejrad.2007.10.026

    CAS  PubMed  Google Scholar 

  63. Staatz G, Nolte-Ernsting CC, Haage P, Tacke J, Rohrmann D, Stollbrink C, Günther RW (2001) Gadolinium-enhanced T(1)-weighted MR urography versus T(2)-weighted (HASTE) MR urography in children. Rofo 173:991–996

    CAS  PubMed  Google Scholar 

  64. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y (2006) Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 24:445–451

    CAS  PubMed  Google Scholar 

  65. Broome DR, Cottrell AC, Kanal E (2007) Response to “Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?”. AJR Am J Roentgenol 189:W234–W235

    PubMed  Google Scholar 

  66. Pharmacovigilance Working Party (PhVWP) of the Committee for Medicinal Products for Human Use (CHMP). Available at https://doi.org/www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con2030232.pdf

  67. Dharnidharka VR, Wesson SK, Fennell RS (2006) Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 22:1395

    PubMed  Google Scholar 

  68. DiCarlo JB, Gupta EA, Solomon AR (2007) A pediatric case of nephrogenic fibrosing dermopathy: improvement after combination therapy. J Am Acad Dermatol 54:914–916

    Google Scholar 

  69. Sanchez-Ross M, Snyder R, Colome-Grimmer MI, Blumberg M, Huttenbach Y, Raimer S (2007) Nephrogenic fibrosing dermopathy in a patient with systemic lupus erythematosus and acute lupus nephritis. Pediatr Dermatol 24:E36–39

    PubMed  Google Scholar 

  70. Gibson SE, Farver CF, Prayson RA (2006) Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 130:209–212

    PubMed  Google Scholar 

  71. Ting WW, Stone MS, Madison KC, Kurtz K (2003) Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139:903–906

    PubMed  Google Scholar 

  72. Morcos SK (2007) Erratum of Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 80:586

    Google Scholar 

  73. Kafi R, Fisher GJ, Quan T, Shao Y, Wang R, Voorhees JJ, Kang S (2004) UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 140:1322–1324

    PubMed  Google Scholar 

  74. Wahba IM, White K, Meyer M, Simpson EL (2007) The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy—report of two cases and review of the literature. Nephrol Dial Transplant 22:631–636

    PubMed  Google Scholar 

  75. Baron PW, Cantos K, Hillebrand DJ, Hu KQ, Ojogho ON, Nehlsen-Cannarella S, Concepcion W (2003) Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 25:204–209

    PubMed  Google Scholar 

  76. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R (2007) Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure—role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2:258–263

    CAS  PubMed  Google Scholar 

  77. Chung HJ, Chung KY (2004) Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol 150:596–597

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas Southwestern Medical Center at Dallas, Veterans Affairs North Texas Health Care System, 4500 S Lancaster Rd., Dallas, TX, 75216, USA

    Jeffrey G. Penfield

Authors
  1. Jeffrey G. Penfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey G. Penfield.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Penfield, J.G. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Pediatr Nephrol 23, 2121–2129 (2008). https://doi.org/10.1007/s00467-008-0862-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-008-0862-6

Keywords

Search

Navigation